8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 28, 2013)

Filed October 28, 2013For Securities:EW

Summary

This Form 8-K filing from Edwards Lifesciences Corporation (EW), dated October 28, 2013, announces the company's financial results for the third quarter of 2013. The primary purpose of this filing is to provide investors with the official release of these results, which were detailed in a press release furnished as Exhibit 99.1. This filing serves as a key communication channel for the company to update the market on its operational and financial performance during the quarter. Investors should note that this report does not contain new operational details beyond what was presented in the press release. The key information for shareholders lies within the referenced press release, which would contain specific figures on revenue, earnings, and any relevant segment performance. This 8-K serves as the official record of the dissemination of that crucial quarterly financial data.

Key Highlights

  • 1Edwards Lifesciences Corporation filed an 8-K on October 28, 2013.
  • 2The filing announces the company's financial results for the third quarter of 2013.
  • 3The press release containing the Q3 2013 financial results is furnished as Exhibit 99.1.
  • 4The information in this 8-K is incorporated by reference from the provided press release.
  • 5The filing confirms the accuracy and official release of the Q3 2013 financial data.
  • 6The Chief Financial Officer, Thomas M. Abate, signed the report.
  • 7This filing is crucial for investors tracking EW's performance in Q3 2013.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report and provide access to Edwards Lifesciences Corporation's financial results for the third quarter of 2013, as detailed in a press release furnished with the filing.

The specific financial details for the third quarter of 2013 are contained within the press release dated October 28, 2013, which is furnished as Exhibit 99.1 to this Form 8-K filing and incorporated by reference.

No, this 8-K filing primarily serves to report the financial results. Any operational updates or management commentary related to the third quarter of 2013 would be found in the accompanying press release (Exhibit 99.1).

The 8-K filing was signed by Thomas M. Abate, Corporate Vice President and Chief Financial Officer of Edwards Lifesciences Corporation.